{
  "label": "clinical_signal_03_ep_012",
  "artifact_type": "signal_episode",
  "artifact_id": "sha256:4b189a6b709cf7cb0785ad568c04784d9928304f5d8d66899ed0985e40778072",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:161174e8025b5c956602ccc4e17b4e677c58230b1b64641f357c400c448b8151"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:54:42.524241",
  "content": "## 2024-05-20 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 192\n- Active: 186\n- Screen Failures Cumulative: 21\n- Withdrawals Cumulative: 6\n\n#### Sites\n- Site 01\n  - Enrolled: 19\n  - Active: 19\n  - Statin Concomitant: 5\n- Site 02\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 3\n- Site 03\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 5\n- Site 04\n  - Enrolled: 13\n  - Active: 13\n  - Statin Concomitant: 3\n- Site 05\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 5\n- Site 06\n  - Enrolled: 11\n  - Active: 11\n  - Statin Concomitant: 3\n- Site 07\n  - Enrolled: 21\n  - Active: 21\n  - Statin Concomitant: 6\n- Site 08\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 4\n- Site 09\n  - Enrolled: 16\n  - Active: 16\n  - Statin Concomitant: 5\n- Site 10\n  - Enrolled: 13\n  - Active: 13\n  - Statin Concomitant: 4\n- Site 11\n  - Enrolled: 18\n  - Active: 18\n  - Statin Concomitant: 4\n- Site 12\n  - Enrolled: 14\n  - Active: 14\n  - Statin Concomitant: 4\n\n### Lab Panels\n- Statin Subgroup\n  - N: 51\n  - ALT (U/L) Mean: 47.2\n  - ALT (U/L) Median: 45.7\n  - AST (U/L) Mean: 41.0\n  - AST (U/L) Median: 41.0\n  - Bilirubin (mg/dL) Mean: 0.73\n  - Bilirubin (mg/dL) Median: 0.72\n  - ALP (U/L) Mean: 61.9\n  - ALP (U/L) Median: 56.0\n  - Creatinine (mg/dL) Mean: 1.07\n  - Creatinine (mg/dL) Median: 0.92\n  - BUN (mg/dL) Mean: 16.8\n  - BUN (mg/dL) Median: 15.4\n  - WBC (K) Mean: 7.7\n  - WBC (K) Median: 7.1\n  - Platelets (K) Mean: 257\n  - Platelets (K) Median: 250\n- Non-Statin Subgroup\n  - N: 123\n  - ALT (U/L) Mean: 22.0\n  - ALT (U/L) Median: 21.4\n  - AST (U/L) Mean: 23.5\n  - AST (U/L) Median: 22.1\n  - Bilirubin (mg/dL) Mean: 0.66\n  - Bilirubin (mg/dL) Median: 0.61\n  - ALP (U/L) Mean: 55.2\n  - ALP (U/L) Median: 61.9\n  - Creatinine (mg/dL) Mean: 1.06\n  - Creatinine (mg/dL) Median: 0.98\n  - BUN (mg/dL) Mean: 14.8\n  - BUN (mg/dL) Median: 12.3\n  - WBC (K) Mean: 6.7\n  - WBC (K) Median: 5.6\n  - Platelets (K) Mean: 234\n  - Platelets (K) Median: 221\n\n### Adverse Events\n- AE ID: AE-0036, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0037, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n- AE ID: AE-0038, Description: abdominal discomfort, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0039, Description: transaminase measurement out of range, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 54\n- ACE Inhibitor Count: 30\n- Metformin Count: 23\n- PPI Count: 17\n- NSAID Count: 12\n- Other Count: 36\n\n### Protocol Deviations\n- PD ID: PD-026, Description: Dose modification without documented PI approval, Severity: moderate, Site: site_07\n\n### Investigator Notes\n- Source document verification complete for prior monitoring visit\n- EDC data entry backlog cleared, queries resolved\n\n### Events\n- IVRS system update deployed, randomization unaffected\n- Bioanalytical lab shipment tracking confirmed for 2 samples\n- Site 03 new coordinator onboarding completed\n\n### Notes\n- Week 12: Statin subgroup hepatic panel shows ALT values at upper range. Non-statin subgroup stable. Routine operations continue.",
  "metadata": {
    "episode_id": "clinical_signal_03_ep_012",
    "scope_id": "clinical_signal_03",
    "timestamp": "2024-05-20T10:00:00",
    "phase": "early_signal",
    "signal_density": "low",
    "episode_type": "signal",
    "layer_name": "signal_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "724335e48952198659b608a79f591f6985cc457d1b0726c271a193e4d218a284",
      "components": {
        "transform": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
        "inputs": "a94b84fbaca9bd62"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
      "components": {
        "transform_id": "cb4ddfa83a38701b",
        "source": "42e76241d396a578",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}